Aravax to communicate results of its Phase 2 clinical trial of novel immunotherapy for the treatment of peanut allergy

Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces it will be communicating topline results from its Phase 2 study of its lead product, PVX108 for the treatment of peanut allergy, at major conferences in the US and Europe in November 2026:

• The Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Arizona from 12 – 16 November. 
• The European Academy of Allergy and Clinical Immunology (EAACI) Food Allergy Anaphylaxis and the European Consortium on Application of Flow Cytometry in Allergy (FAAM-EUROBAT-ISMA) Congress in Utrecht, Netherlands from 19 – 21 November. 

Dr Pascal Hickey, CEO of Aravax, said, “We are excited to be able to share new Phase 2 top-line data with a wide audience at these two important scientific meetings in November. We believe that PVX108 has the potential to provide a highly differentiated treatment option by minimizing the risks of acute allergic reactions during treatment which complicate whole-allergen approaches, whilst promoting immune tolerance.”

PVX108 is a next-generation immunotherapy which uses proprietary peptides designed to precisely retrain the immune system to tolerate peanut whilst avoiding treatment-induced acute allergic reactions. It has been awarded FDA Fast Track designation for the treatment of peanut allergy.

Aravax’s PVX108 Phase 2 study (NCT05621317) was conducted across trial sites in the US and Australia. Trial participants with peanut allergy were enrolled into two cohorts: a pilot safety adolescent cohort; and a primary efficacy cohort in children aged four to eleven years. The trial was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of PVX108 when administered intradermally in monthly doses over a 12-month period.